2025 Q2 -tulosraportti
227 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 388 | - | - | ||
| 4 612 | - | - | ||
| 165 | - | - | ||
| 6 | - | - | ||
| 269 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 t sittenCould there be a real downturn tomorrow after an “anti-climax” announcement about missteps from management's side, or can people overlook it? No matter what, it's win-win for me personally, so more can be bought before the concert on the 27th.😊
4 min sitten · Muokattu4 min sitten · MuokattuThere is still annual report coming this week wednesday. After that we can start waiting for new target prices from Analyst group "We will return with an updated equity research report of Circio following the FY2025 report". This week is going to be good for price, even without abstracts. Edit: If there is still that short open when new target prices come, only way out for Qube is to pay asking price. My guess is by end of week there is increase ln value and someone gets fired at Qube's office for shorting Circio.
·4 t sittenThe abstracts come 27 April see Circio's website.
·4 t sittenA 2.0 version of a previous speculative prediction.. Who could the Big Pharma partner be? (feasibility study since November) And how well would circVec fit into their current programs? #Pfizer: Relevant programs: Hemophilia A/B gene therapy (AAV-based) Several internal programs via acquisitions (e.g. Bamboo Therapeutics) Known problems in the field: High dose = liver toxicity Variable effect over time Immune response to AAV Where circVec fits perfectly: Lower dose = less toxicity More stable expression = better durability Timing-fit: VERY high Pfizer is directly facing problems circVec tries to solve #Roche Relevant programs: Spark Therapeutics (acquired by Roche) Eye gene therapy (AAV) — one of the most mature areas Known problems: Limited expression in retina Dose constraints (the eye is sensitive) circVec edge: Circio has eye-data with 50x expression It is directly applicable in the Roche/Spark pipeline Timing-fit: EXTREMELY high “almost too perfect” #AstraZeneca Relevant programs: Quietly building gene therapy pipeline Focus on cardio + rare diseases Situation: Still in building phase Fewer mature AAV-assets circVec role: Can be used early in pipeline design Not necessarily as a “fix”, but as a “design choice” Timing-fit: MEDIUM More forward-looking than problem-solving #Eli Lilly Relevant programs: Eli Lilly recently acquired ORNA Therapeutics which also works with circRNA. Classic Big Pharma strategy: “let multiple technologies compete internally” Situation: Less mature AAV pipeline than Pfizer/Roche Still in strategy/building phase However, constantly and aggressively looking for new tech. circVec role: Exploratory tech scouting Timing-fit: MEDIUM
·4 t sittenCircio is in the process of moving from research phase to commercial visibility, a point where biotech is historically significantly re-priced. The platform technology provides both scalability and attractive partner potential, while the market still prices the case conservatively. With several upcoming triggers and increasing attention, I believe there are good conditions for a rapid re-pricing. My assessment is clear: The probability of a doubling from today's level within a relatively short time appears high given the current position and momentum. Fundamental conditions are strengthening, the market is lagging. This is typically the phase where the largest movements occur.- ·5 t sittenLet me hear your thoughts on tomorrow, and 12-24 months out :)
·4 t sittenTomorrow is a non-event, but also the countdown to something big. As Raketmanden mentions, it's now time for gardening and rosé wine, and in 24 months you can look at your gardener, while the Pingus PSI is poured into the glass by the butler. Pingus is also originally Danish, so just fill up!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
227 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenCould there be a real downturn tomorrow after an “anti-climax” announcement about missteps from management's side, or can people overlook it? No matter what, it's win-win for me personally, so more can be bought before the concert on the 27th.😊4 min sitten · Muokattu4 min sitten · MuokattuThere is still annual report coming this week wednesday. After that we can start waiting for new target prices from Analyst group "We will return with an updated equity research report of Circio following the FY2025 report". This week is going to be good for price, even without abstracts. Edit: If there is still that short open when new target prices come, only way out for Qube is to pay asking price. My guess is by end of week there is increase ln value and someone gets fired at Qube's office for shorting Circio.
- ·4 t sittenThe abstracts come 27 April see Circio's website.
- ·4 t sittenA 2.0 version of a previous speculative prediction.. Who could the Big Pharma partner be? (feasibility study since November) And how well would circVec fit into their current programs? #Pfizer: Relevant programs: Hemophilia A/B gene therapy (AAV-based) Several internal programs via acquisitions (e.g. Bamboo Therapeutics) Known problems in the field: High dose = liver toxicity Variable effect over time Immune response to AAV Where circVec fits perfectly: Lower dose = less toxicity More stable expression = better durability Timing-fit: VERY high Pfizer is directly facing problems circVec tries to solve #Roche Relevant programs: Spark Therapeutics (acquired by Roche) Eye gene therapy (AAV) — one of the most mature areas Known problems: Limited expression in retina Dose constraints (the eye is sensitive) circVec edge: Circio has eye-data with 50x expression It is directly applicable in the Roche/Spark pipeline Timing-fit: EXTREMELY high “almost too perfect” #AstraZeneca Relevant programs: Quietly building gene therapy pipeline Focus on cardio + rare diseases Situation: Still in building phase Fewer mature AAV-assets circVec role: Can be used early in pipeline design Not necessarily as a “fix”, but as a “design choice” Timing-fit: MEDIUM More forward-looking than problem-solving #Eli Lilly Relevant programs: Eli Lilly recently acquired ORNA Therapeutics which also works with circRNA. Classic Big Pharma strategy: “let multiple technologies compete internally” Situation: Less mature AAV pipeline than Pfizer/Roche Still in strategy/building phase However, constantly and aggressively looking for new tech. circVec role: Exploratory tech scouting Timing-fit: MEDIUM
- ·4 t sittenCircio is in the process of moving from research phase to commercial visibility, a point where biotech is historically significantly re-priced. The platform technology provides both scalability and attractive partner potential, while the market still prices the case conservatively. With several upcoming triggers and increasing attention, I believe there are good conditions for a rapid re-pricing. My assessment is clear: The probability of a doubling from today's level within a relatively short time appears high given the current position and momentum. Fundamental conditions are strengthening, the market is lagging. This is typically the phase where the largest movements occur.
- ·5 t sittenLet me hear your thoughts on tomorrow, and 12-24 months out :)·4 t sittenTomorrow is a non-event, but also the countdown to something big. As Raketmanden mentions, it's now time for gardening and rosé wine, and in 24 months you can look at your gardener, while the Pingus PSI is poured into the glass by the butler. Pingus is also originally Danish, so just fill up!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 388 | - | - | ||
| 4 612 | - | - | ||
| 165 | - | - | ||
| 6 | - | - | ||
| 269 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
227 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenCould there be a real downturn tomorrow after an “anti-climax” announcement about missteps from management's side, or can people overlook it? No matter what, it's win-win for me personally, so more can be bought before the concert on the 27th.😊4 min sitten · Muokattu4 min sitten · MuokattuThere is still annual report coming this week wednesday. After that we can start waiting for new target prices from Analyst group "We will return with an updated equity research report of Circio following the FY2025 report". This week is going to be good for price, even without abstracts. Edit: If there is still that short open when new target prices come, only way out for Qube is to pay asking price. My guess is by end of week there is increase ln value and someone gets fired at Qube's office for shorting Circio.
- ·4 t sittenThe abstracts come 27 April see Circio's website.
- ·4 t sittenA 2.0 version of a previous speculative prediction.. Who could the Big Pharma partner be? (feasibility study since November) And how well would circVec fit into their current programs? #Pfizer: Relevant programs: Hemophilia A/B gene therapy (AAV-based) Several internal programs via acquisitions (e.g. Bamboo Therapeutics) Known problems in the field: High dose = liver toxicity Variable effect over time Immune response to AAV Where circVec fits perfectly: Lower dose = less toxicity More stable expression = better durability Timing-fit: VERY high Pfizer is directly facing problems circVec tries to solve #Roche Relevant programs: Spark Therapeutics (acquired by Roche) Eye gene therapy (AAV) — one of the most mature areas Known problems: Limited expression in retina Dose constraints (the eye is sensitive) circVec edge: Circio has eye-data with 50x expression It is directly applicable in the Roche/Spark pipeline Timing-fit: EXTREMELY high “almost too perfect” #AstraZeneca Relevant programs: Quietly building gene therapy pipeline Focus on cardio + rare diseases Situation: Still in building phase Fewer mature AAV-assets circVec role: Can be used early in pipeline design Not necessarily as a “fix”, but as a “design choice” Timing-fit: MEDIUM More forward-looking than problem-solving #Eli Lilly Relevant programs: Eli Lilly recently acquired ORNA Therapeutics which also works with circRNA. Classic Big Pharma strategy: “let multiple technologies compete internally” Situation: Less mature AAV pipeline than Pfizer/Roche Still in strategy/building phase However, constantly and aggressively looking for new tech. circVec role: Exploratory tech scouting Timing-fit: MEDIUM
- ·4 t sittenCircio is in the process of moving from research phase to commercial visibility, a point where biotech is historically significantly re-priced. The platform technology provides both scalability and attractive partner potential, while the market still prices the case conservatively. With several upcoming triggers and increasing attention, I believe there are good conditions for a rapid re-pricing. My assessment is clear: The probability of a doubling from today's level within a relatively short time appears high given the current position and momentum. Fundamental conditions are strengthening, the market is lagging. This is typically the phase where the largest movements occur.
- ·5 t sittenLet me hear your thoughts on tomorrow, and 12-24 months out :)·4 t sittenTomorrow is a non-event, but also the countdown to something big. As Raketmanden mentions, it's now time for gardening and rosé wine, and in 24 months you can look at your gardener, while the Pingus PSI is poured into the glass by the butler. Pingus is also originally Danish, so just fill up!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 388 | - | - | ||
| 4 612 | - | - | ||
| 165 | - | - | ||
| 6 | - | - | ||
| 269 | - | - |
Välittäjätilasto
Dataa ei löytynyt